


Journal Pre-proof

COVID-19 vaccination in the setting of mastocytosis - Pfizer-BioNTech mRNA vaccine is safe and well-tolerated

Nikolaos Lazarinis, MD, PhD, Apostolos Bossios, MD, PhD, Theo Gülen, MD, PhD



PII: S2213-2198(22)00117-9

DOI: <https://doi.org/10.1016/j.jaip.2022.01.037>

Reference: JAIP 4076

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 12 November 2021

Revised Date: 4 January 2022

Accepted Date: 17 January 2022

Please cite this article as: Lazarinis N, Bossios A, Gülen T, COVID-19 vaccination in the setting of mastocytosis - Pfizer-BioNTech mRNA vaccine is safe and well-tolerated, *The Journal of Allergy and Clinical Immunology: In Practice* (2022), doi: <https://doi.org/10.1016/j.jaip.2022.01.037>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

COVID-19 vaccination in the setting of mastocytosis - Pfizer-BioNTech mRNA vaccine is safe and well-tolerated

Nikolaos Lazarinis MD, PhD^{1,2}, Apostolos Bossios MD, PhD^{1,2}, *Theo Gülen MD, PhD^{1,2,3,4}

¹Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge, Stockholm, Sweden.

²Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

³Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

⁴Mastocytosis Center Karolinska, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden

*Corresponding Author:

Theo Gülen, MD, PhD

Department of Respiratory Medicine and Allergy, K85,

Karolinska University Hospital Huddinge, Stockholm, SE-14186 Sweden

Email: theo.gulen@regionstockholm.se; Theo.Gulen@ki.se

Phone number: +46 737 765476

Funding sources: T. Gülen was supported by grants from the Konsul T.H.C. Bergh Foundation, Sweden, the Swedish Society of Medicine, and the Stockholm County Council Research Funds (ALF), Sweden. N. Lazarinis was supported by a grant from the Konsul T.H.C. Bergh Foundation, Sweden. A. Bossios was supported by a Swedish Heart-Lung Foundation fellowship (20200619).

Conflict of Interest Disclosures: The authors declare that they have no relevant conflicts of interest.

Manuscript Word Count: 1099

Capsule summary word count: 40

References: 12

Figures/Tables: 1

Clinical implications:

Here, we report our experience with COVID-19 vaccination in a series of 73 fully vaccinated patients with mastocytosis. Pfizer-BioNTech vaccine was safe under antihistamine premedication and an extended observation of 45 minutes, as only 2.7% reacted with mild, immediate symptoms.

Mastocytosis refers to a heterogeneous group of disorder characterized by accumulation and activation of mast cells (MCs) in the skin and/or internal organs (1). Patients with clonal MCs limited to the skin are classified as having cutaneous mastocytosis (CM), whereas in systemic mastocytosis (SM), at least 1 extracutaneous organ is involved (1). Furthermore, monoclonal MC activation syndrome (MMAS) is a rare variant of this disorder, in which patients have clonal MCs but do not meet criteria for SM (1).

Patients with mastocytosis typically present with a range of recurrent MC mediator-related local or systemic clinical symptoms including pruritus, flushing and life-threatening anaphylaxis (2). Elicitors of anaphylaxis include in most mastocytosis patients Hymenoptera-venom stings, but rarely drugs and foods (2). Nevertheless, data related to the tolerance of vaccinations in adult mastocytosis patients are scanty (3). Recent development of COVID-19 vaccines has actualized this issue and the question has been raised whether mastocytosis patients will safely tolerate COVID-19 vaccines because most of these patients are prone to anaphylaxis as well as these vaccines have been initially linked to an increased risk for allergic reactions in patients with previous allergies (4). Although some previous studies reported that COVID-19 vaccines were well-tolerated in mastocytosis (5,6), the paucity of the enrolled subjects in the studies makes generalizability difficult. Hence, this retrospective study was conducted to evaluate safety and prevalence of COVID-19 mRNA vaccine-related immediate reactions in a series of 73 fully vaccinated (two doses) mastocytosis patients.

Between January 2006 and May 2021, 512 consecutive adult patients have been referred to the Mastocytosis Centre Karolinska due to clinically suspected MC disorders including patients with mastocytosis in the skin (MIS), patients with severe anaphylaxis or patients with elevated serum baseline tryptase levels (sBT) of unknown origin. The final diagnoses of SM or MMAS were obtained in a total of 255 patients following WHO criteria (1). Moreover, sBT and total IgE levels were measured, and patients underwent a comprehensive allergy work-up to confirm atopic status and history of anaphylaxis.

Of 255 patients, 73 were identified for COVID-19 vaccination. Patients either themselves took contact with the clinic due to vaccine-related anxiety or patients who were continuously monitored in the clinic, for instance due to venom immunotherapy (VIT) or treatment with biological drugs were included. Of 73 enrolled patients, 62 were diagnosed with SM (60 patients had indolent SM, 1 patient had SM with hematologic neoplasm and 1 had aggressive SM); whereas 2 patients obtained diagnosis of MIS since they refused to undergo bone marrow investigation. Additionally, 9 patients had diagnosis of MMAS (Table 1). Informed consent was obtained according to the guidelines of the Stockholm's Ethics Review Board (Dnr: 2011/1750/31/3 and Dnr: 2018/2621-31).

All vaccinations were performed in our allergy outpatient clinic using a special protocol, which is derived from our VIT setting for patients with mastocytosis (7). Accordingly, all patients received premedication with antihistamine (AH) (2 tablets of Desloratadine® 5mg) 30-60 minutes prior to vaccination (51 patients were on scheduled AHs and took 2 additional tablets). Subsequently, 30 µg (0.3 ml) of Pfizer-BioNTech (Comirnaty®) vaccine (which was the only available vaccine at that time) was given. Afterwards, patients remained for a 45-minute observation. The second doses were applied 3-4 weeks after the first dose. The vaccine was administered at least 7-days after or before in patients those who were treated with VIT or biological drugs (e.g., omalizumab).

In our series, two of 73 patients (2.7%) developed mild, immediate (within 20-40 minutes after vaccination) reactions in 3 of 146 injections. Both patients were females and experienced facial flushing, tingling in mouth/tongue, a sense of general discomfort; however, cardio-respiratory parameters were stable. Patients responded well to two extra AH tablets (Desloratadine® 5mg) and observed an additional 2 hours without further progress of their reactions. Both patients had diagnosis of indolent SM and had no history of anaphylaxis or atopies. Interestingly, 1 patient reacted to both doses (recently, even reacted with the 3rd dose) with same reaction pattern, whereas the second patient only reacted to first dose. Moreover, in our cohort, none of the patients developed severe, immediate allergic reactions requiring epinephrine. In a recent study on highly allergic non-mastocytosis

patients (8), immediate reaction rate was 2%, which is comparable to 2.7% found in this study. Furthermore, the rate of delayed hypersensitivity reactions (including skin eruption, itching or urticaria) was 14.7% in this highly allergic cohort (8). Interestingly, however, none reported delayed hypersensitivity reactions in our cohort, as documented prior to the second dose of immunization (i.e., ≥ 3 weeks after the first dose). Nevertheless, non-allergic adverse reactions including injection-site pain/tenderness, myalgia, malaise, chills were common among our patients.

The main strength of this single-center study was the homogeneity of the subjects enrolled and protocols applied. Patients were investigated in a standardized manner and underwent a comprehensive allergy work-up in our center as well as received COVID-19 vaccination from the same manufacturer using a standard protocol. Another distinguishing feature of this study was that our vaccination cohort included high-risk patients not only because of mastocytosis, but also 66% (48/73) had history of anaphylaxis (some with recurrent episodes). Of 73 patients, 35 (48%) had history of venom-induced anaphylaxis, whereas only one had drug-induced anaphylaxis (caused by diclofenac). However, our cohort contained no patients with a history of anaphylaxis with prior vaccinations or polyethylene glycol/polysorbate.

At present, it is difficult to assess whether premedication with AH might have been lowered the risk for potential anaphylaxis. We do not routinely recommend premedication with AH in mastocytosis patients, for instance, prior to other vaccinations. Nevertheless, some of mastocytosis patients are regularly on AH prophylaxis. Therefore, randomized trials are needed to assess the exact role of premedication with AH in mastocytosis patients before providing general or patient-based recommendations. Until then, the usage of AH as premedication prior to COVID-19 vaccination should be encouraged, which is also in compliance with current recommendations regarding COVID-19 vaccination in mastocytosis (9).

In conclusion, we report that in our settings, COVID-19 vaccination of mastocytosis patients was safe and well-tolerated, even those with an anaphylactic history. Recently, 39 of 73 (53%) patients received a third dose of Pfizer-BioNTech vaccine and only 1 (the patient who reacted to the first two doses) reacted with mild symptoms. Thus, we suggest that because anaphylaxis is more severe in mastocytosis (2), patients should be given premedication with an AH prior to COVID-19 vaccination and should pursue their daily medications (if any). Further, we recommend an extended observation period of 45 minutes after vaccination. Moreover, COVID-19 vaccinations can be administered in vaccine sites with resuscitation equipment readily available and have staff trained in recognizing and managing anaphylaxis.

Acknowledgments: We thank all our colleagues and nurses in the Karolinska University Hospital, Allergy Outpatient Clinic for the planning and implementation of the COVID-19 vaccination in patients with high allergy risk, including mastocytosis.

REFERENCES

- 1 - Gulen T, Hagglund H, Dahlen B, Nilsson G. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. *J Intern Med* 2016;279:211-28.
- 2 - Gulen T, Hagglund H, Dahlen B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis—a single-centre experience. *Clin Exp Allergy* 2014;44:121-9.
- 3 - Zanoni G, Zanotti R, Schena D, Sabbadini C, Opri R, Bonadonna P. Vaccination management in children and adults with mastocytosis. *Clin Exp Allergy*. 2017;47:593–596.
- 4 - Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(2):46-51. 10.15585/mmwr.mm7002e1
- 5 – Kaakati R, Khokhar D, Akin C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. *J Allergy Clin Immunol Pract*. 2021 Aug;9(8):3198-3199.
- 6 – Rosman Y, Lavi N, Meir-Shafir K, Lachover-Roth I, Cohen-Engler A, Mekori YA, Confino-Cohen R. Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders. *J Allergy Clin Immunol Pract*. 2021 Sep;9(9):3487-3489.
- 7 - Jarkvist J, Salehi C, Akin C, Gulen T. Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection. *Allergy* 2020;75(1):169-77.
- 8 - Shavit R, Maoz-Segal R, Iancovici-Kidon M, Offengenden I, Haj Yahia S, Machnes Maayan D, et al. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. *JAMA Netw Open*. 2021 Aug 2;4(8):e2122255.
- 9 - Bonadonna P, Brockow K, Niedozytko M, Elberink HO, Akin C, Niedozytko B, et al. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)Cell Diseases (AIM). *J Allergy Clin Immunol Pract*. 2021 Jun;9(6):2139-2144.

Table 1: Demographics, epidemiology and clinical and laboratory characteristics of enrolled subjects

	Total cohort (n = 73)	SM (n = 62)	MIS (n = 2)	MMAS (n = 9)
Female gender, n (%)	38/73 (52%)	35/62 (56%)	2/2 (100%)	4/9 (44%)
Age at diagnosis, median (range)	54 (18–79)	54 (18–79)	n/a	47 (36–67)
Baseline tryptase (ng/mL), median (range)	19 (3.2–160)	22 (5.3–160)	n/a	8.5 (3.2–15)
Total IgE (kU/L), median (range)	16 (1–1000)	16 (1–1000)	n/a	28 (8.3–250)
Presence of MC aggregates in bone marrow biopsy, n (%)	29 (41%) (2 NA)	29 (47%)	2 NA	0 (0)
Presence of atypical morphology in bone marrow biopsy, n (%)	61 (86%) (2 NA)	58 (94%)	2 NA	3 (33%)
Presence of CD25 in bone marrow MCs, n (%)	71 (100%) (2 NA)	62 (100%)	2 NA	9 (100)
Presence of D816V mutation, n (%)	59 (81%)	55 (89%)	2 (100%)	2 (29%)
Presence of mastocytosis skin lesions, n (%)	38 (52%)	36 (58%)	n/a	n/a
Presence of atopy, n (%)	19 (26%) (1 n/a)	16 (26%)	1 (50%)	2 (25%) (1 n/a)
Presence of atopic diseases (rhinoconjunctivitis and/or asthma), n (%)	16 (22%) (1 n/a)	13 (21%)	1 (50%)	2 (25%) (1 n/a)
History of any kind of anaphylaxis, n (%)	48 (66%)	39 (63%)	None	9 (100%)
History of venom-induced anaphylaxis, n (%)	35/73 (48%)	28 /62 (45%)	None	7/9 (78%)
History of food/drug-induced anaphylaxis, n (%)	2/73 (2.7%)	2/62 (3%)	None	None
History of idiopathic anaphylaxis, n (%)	11/73 (15%)	9/62 (15%)	None	2/9 (22%)

Abbreviations: SM, Systemic mastocytosis; MIS, Mastocytosis in the skin; MMAS, monoclonal mast cell activation syndrome; MC, Mast cell; n/a, not applicable; NA, not analysed.